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Abstract
We describe novel CHRDL1 mutations in ten families with X-linked megalocornea (MGC1). Our mutation-positive cohort
enabled us to establish ultrasonography as a reliable clinical diagnostic tool to distinguish between MGC1 and primary
congenital glaucoma (PCG). Megalocornea is also a feature of Neuha¨user or megalocornea-mental retardation (MMR)
syndrome, a rare condition of unknown etiology. In a male patient diagnosed with MMR, we performed targeted and whole
exome sequencing (WES) and identified a novel missense mutation in CHRDL1 that accounts for his MGC1 phenotype but
not his non-ocular features. This finding suggests that MMR syndrome, in some cases, may be di- or multigenic. MGC1
patients have reduced central corneal thickness (CCT); however no X-linked loci have been associated with CCT, possibly
because the majority of genome-wide association studies (GWAS) overlook the X-chromosome. We therefore explored
whether variants on the X-chromosome are associated with CCT. We found rs149956316, in intron 6 of CHRDL1, to be the
most significantly associated single nucleotide polymorphism (SNP) (p = 6.8161026) on the X-chromosome. However, this
association was not replicated in a smaller subset of whole genome sequenced samples. This study highlights the
importance of including X-chromosome SNP data in GWAS to identify potential loci associated with quantitative traits or
disease risk.
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Introduction
X-linked megalocornea (MGC1; MIM 309300) is an inherited
congenital disorder, characterised by bilateral enlarged corneas
with a horizontal diameter of $13 mm (measured after the age of
two years) and reduced central corneal thickness in the absence of
raised intraocular pressure (IOP) [1]. Adult-onset cataract typically
develops between 30–50 years [2]. Other secondary changes
include mosaic corneal degeneration (shagreen), corneal arcus
juvenilis, lens dislocation and mild iris atrophy with pigment
dispersion [3]. The condition was genetically linked to the long
arm of the X-chromosome over twenty years ago (Xq12-q26;
MGC1) [2,4] but the underlying genetic cause, mutations in
CHRDL1 (MIM 300350), has only recently been discovered [3].
CHRDL1 encodes ventroptin (or neuralin-1, neurogenesin-1,
chordin-like 1), a secreted bone morphogenetic protein (BMP)
antagonist [5]. To date, presumed loss-of-function mutations in
CHRDL1 have been described in eight unrelated families affected
with MGC1 [3,6].
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Distinguishing megalocornea from primary congenital glauco-
ma (PCG) in infants is clinically challenging due to overlapping
phenotypic features. PCG is a genetically heterogeneous condi-
tion, often associated with a broad spectrum of additional
phenotypes [7]. PCG is characterised by high IOP and enlarged
globe size (buphthalmos) resulting from an obstruction of aqueous
outflow from the anterior segment. Late detection and delayed
treatment lead to irreversible and progressive damage to the optic
nerve and permanent visual loss can occur [8]. Genetic analysis of
the condition has resulted in identification of three PCG loci on
chromosomes 2p22 (GLC3A, MIM 613086) [9], 1p36 (GLC3B,
MIM 600975) [10] and 14q24.3-q31.1 (GLC3C, GLC3D, MIM
613085, MIM 613086) [11]. Recessive mutations in CYP1B1
(GLC3A) are the most common cause, especially in populations
where consanguinity is common, such as the Saudi population
[12]. Variants in MYOC have also been associated with PCG
either independently or in association with CYP1B1 [13].
However, variants in this gene are more commonly associated
with juvenile and adult-onset primary open angle glaucoma
(GLC1A, MIM 137750) [14]. Recessive mutations in LTBP2
(GLC3D, MIM 613086) have been identified as a cause of early-
onset glaucoma secondary to congenital megalocornea in multiple
consanguineous families [15–17]. Notably, in the eight reported
unrelated MGC1 families with CHRDL1 mutations, none of the
affected males (ranging from 8–72 years of age) had raised IOP,
glaucoma or significant visual loss [3,6].
Megalocornea is a defining feature of megalocornea-mental
retardation (MMR) syndrome [MIM 249310], also known as
Neuha¨user syndrome [18]. The condition is rare and characterised
by megalocornea in addition to neurological symptoms including
intellectual disability (ID), hypotonia and seizures [1,18,19].
Syndromic facial features are also described and include a
prominent forehead, broad nasal root, epicanthus, large low set
ears, long upper lip and anteverted nostrils [1]. The genetic cause
of MMR syndrome is currently unknown. The majority of
reported cases are consistent with an autosomal recessive mode of
inheritance or a de novo cause, and the phenotypic heterogeneity
associated with cases reported to date suggests that the condition
may be genetically heterogeneous [19].
Reduced central corneal thickness (CCT) is a common feature
of all MGC1 patients with a CHRDL1 mutation [3,6]. In the
general population, CCT is known to be a highly heritable,
normally distributed quantitative trait, and is the focus of many
genome-wide association studies (GWAS) because it is known to be
a major risk factor and endophenotype for open-angle glaucoma,
one of the leading causes of irreversible blindness worldwide [20–
25]. The X-chromosome is commonly excluded from such GWAS
analysis [26] and given that reduced CCT is a key feature of
MGC1, here we tested whether any common variants on the X-
chromosome influence CCT in the general population.
Materials and Methods
Study subjects and clinical examination
All investigations were conducted in accordance with the
principles of the Declaration of Helsinki. The study was approved
by the following local ethics committees; Moorfields and
Whittington Hospital UK, The Royal Victorian Eye and Ear
Hospital Australia, Odense University Hospital Denmark and
University Hospital of Wales UK. Informed written consent,
including permission to publish photographs, was obtained from
all participating individuals or parental guardians on behalf of the
minors enrolled in this study. Blood samples were donated and
genomic DNA was extracted from peripheral blood lymphocytes
using conventional methodologies. Patients and their relatives
were clinically assessed by experienced ophthalmologists. Standard
evaluation consisted of detailed ophthalmic examination and the
additional measurement of the axial length of the eye and imaging
of the anterior segment of the eye performed with ocular
coherence tomography (OCT; Visante, Carl Zeiss Meditec), b-
scan ultrasonography, and optical interferometry (IOLMaster,
Carl Zeiss Meditec). Proband of Family K was clinically assessed
by a geneticist (DTP), a paediatric ophthalmologist (DL) and a
paediatrician (MG). He had standard MRI with a 1.5 Tesla
scanner.
Sanger sequencing
CHRDL1 was directly Sanger sequenced from PCR amplimers
as previously described [3]. Segregation analyses of disease-
associated variants in CHRDL1 were tested in additional family
members, where available, by direct sequencing of the specific
exons carrying the mutation. The extent of the deletions
encompassing CHRDL1 was refined by targeted proximal and
distal PCRs amplifying the CHRDL1 flanking genes RGAG1 and
PAK3 (Families I and J). Exon 4 of the proximal gene RGAG1 was
amplified with primers F: 59-AAGGGTGAAGGCAACAAGG-39
and R: 59-GCAAAGTGTCTTGATCTGCTAAG-39, and exon 1
of the distal gene PAK3 was amplified with primers F: 59-
AGCAGAGAAGGGCTAGGGAG-39 and R: 59-GTCTAGGG-
\TTTGACCAAGCG-39. To confirm the deletion identified in
Family H, a long range PCR was performed using BIO-X-ACT
Long DNA Polymerase (Bioline) according to the manufacturer’s
recommendations with primers F: 59-TGAAGCCTAGAGATG-
CAAAGTG-39 in intron 4 and R: 59-GATGGCCACAGCT-
CAGTCTA-39 in intron 5. To determine the breakpoint positions,
the resulting long range PCR product was directly Sanger
sequenced. CHRDL1 cDNA is numbered in accordance with
Ensembl transcript ID ENST00000372042, with +1 correspond-
ing to the A of the ATG translation initiation codon in the
reference sequences.
Whole Exome Sequencing (WES)
WES was performed using Illumina TruSeq exome enrichment
(v3) and a HiSeq2000 sequencer (Illumina). Reads were aligned to
the hg19 human reference sequence using Novoalign (Novocraft,
www.novocraft.com) version 2.05. The ANNOVAR tool (Open-
Bioinformatics) was used to annotate SNPs and small insertions/
deletions. Filtering was performed to identify variants with a minor
allele frequency (MAF)#0.01 in 1000 Genomes Project (www.
1000genomes.org/), 6500 NHLBI Exome Sequencing Project
(http://evs.gs.washington.edu/EVS/), and our internal control
dataset consisting of 304 exomes. Variants were then prioritized
based on their effects on the protein function (frameshift, non-
synonymous, splice site, and synonymous). WES analysis was also
extended to include 59UTR and 39UTR variants, where covered.
Variants were then cross-referenced with genes that have been
reported to be associated with ID and/or hypotonia and/or
seizures and/or epilepsy. The table of candidate genes was
generated using the KEGG disease database (www.genome.jp/
kegg/) and with reference to the report by Piton et al. [27]. All rare
variants identified by WES in Individual III:4 (Family K) in genes
associated with the neurological phenotypes were verified by PCR
amplification and Sanger sequencing using standard methodolo-
gies (primer sequences are available on request). Segregation of the
rare variants was tested in the proband’s mother (Individual II:2)
by the same method (Table S1 in File S1).
Phenotypes Associated with CHRDL1
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In silico analysis
Non-synonymous missense variants identified were scored for
likely pathogenicity using SIFT (http://sift.jcvi.org/), PolyPhen2
(http://genetics.bwh.harvard.edu/pph2/) and Blosum62.
Association study
To determine whether any common variants on the X-
chromosome influence CCT in the general population, we
analysed SNP array genotyping data from the TwinsUK cohort
[28]. Subjects were genotyped in two different batches of
approximately the same size, using two genotyping platforms
from Illumina: 300K Duo and HumanHap610-Quad arrays.
CCT was measured in this cohort using ultrasound pachymetry
and recorded for both eyes. Measurements were performed using
a DGH Technology (model 500). Data collected from 1,957
female Caucasian participants were analysed. Whole genome
imputation of the genotypes (2,729 SNPs) was performed using
1000G haplotypes with the IMPUTE v2 software. Stringent
quality control (QC) measures were implemented prior the
imputation, including minimum genotyping success rate (.95%)
and Hardy-Weinberg equilibrium (P.1026). Regression analysis
for association was performed using mach2qtl and the results were
adjusted for age effects and family relatedness among the samples.
We checked whether this association could be replicated in a
subset of directly whole genome sequenced individuals, made
available through the UK10K project (http://www.uk10k.org/).
A total of 760 female participants with both sequencing and
phenotyping data were analysed. A regression model for
association was fitted using PLINK (http://pngu.mgh.harvard.
edu/,purcell/plink/) using as predictor each single variant and as
outcome CCT adjusted for age effects.
Results
MGC1 families
We ascertained ten new families (A–J) with a diagnosis of
MGC1 (Figure 1; Table 1), the largest cohort reported to date.
Ophthalmic features of all patients are described in Table 1.
Consistent with our previous findings [3], all patients were
identified as having large horizontal corneal diameters (ranging
from 13–16 mm, white to white) and a below average CCT,
ranging from 346–475 mm with the mean CCT being 418 mm
(1SD=33 mm; number eyes measured = 30) (Table 1 and [3]).
The reported mean value for CCT in normal male and female
adult eyes is 535 mm (1SD=31 mm) [29]. Deep anterior chamber
depths were noted in all examined MGC1 subjects, ranging from
4.30–6.50 mm (Table 1). In the normal population of predomi-
nantly European children (mean age 6.7 years), the mean axial
length in right eyes was 22.61 (+/20.02) mm and the mean
anterior chamber depth was 3.34 (+/20.01) mm [30]. In an older
population of white adults (.65 years) mean axial length and
anterior chamber depth were found to be 23.69 (+/21.16) mm
and 3.11 (+/20.37) mm, respectively [31]. IOPs for all MGC1
subjects were determined to be within normal limits. Cataract
surgery had been performed in all three individuals above the age
of 40 years. Additional secondary features of the condition
including shagreen, arcus juvenilis, and mild iris atrophy with
pigment dispersion were also age-related (Table 1; Figure S1 in
File S1).
Novel CHRDL1 mutations causing MGC1
For each affected proband (Families A–J), CHRDL1 exons and
intron-exon boundaries were screened by bi-directional Sanger
sequencing. In total, ten CHRDL1 mutations were identified in
each of the ten respective families investigated (Figure 1; Table 2).
Affected Individual V:4 from Family A was identified as
harbouring a novel missense mutation in CHRDL1, c.872G.A,
p.(Cys291Tyr). Ventroptin has three highly conserved cysteine-
rich von Willebrand factor, type C (VWFC) domains, and Cys291
is within the third domain (Figures 1A, 2D and S2 in File S1). A
strong X-linked family history of megalocornea is reported in
Family A, however further samples were not available for
segregation analysis. Secondary changes in adults with megalo-
cornea include an appearance similar to pigment dispersion
syndrome, but without a Krukenberg spindle on the corneal
endothelium. Proband (V:4) was a high myope (RE 28.00, LE 2
9.00), who exhibited unusually marked posterior iris bowing with
atrophy, peripheral iris transillumination defects and increased
trabecular meshwork pigmentation (Figure S1 in File S1). Aged 43
years he had bilateral phacodonesis with nuclear sclerotic
cataracts, but normal pressures and no evidence of glaucomatous
optic neuropathy.
The proband in Family B (Individual IV:5) was found to have a
unique hemizygous nonsense mutation in CHRDL1, c.240T.A,
p.(Cys80*). Segregation analysis revealed that the proband’s
mother (III:7), maternal grandmother (II:5) and maternal half
great aunt (III:2) were all heterozygous carriers of this mutation.
His sister (IV:4) was found to be wild-type for the variant.
Interestingly, affected relatives of this Danish family were
originally reported in the 1960s [32]. The proband’s affected
great maternal grandfather, Individual I:2 (Figure 1A), corre-
sponds with Individual IV-7 in the original article with a greatly
extended version of the pedigree spanning 7 generations and
detailing many affected males [32].
In Family C, Individual III:I and his maternal grandfather (I:1)
were found to have a novel 2 bp deletion affecting the splice
acceptor site of CHRDL1 exon 12; c.1247-1_1247del. This
mutation is predicted to cause aberrant pre-mRNA splicing of the
CHRDL1 transcript in vivo. His two younger brothers have also
been diagnosed with the same condition; however their DNA
samples were not available for testing (Figure 1A). The probands
in Family D (Individual II:1) and Family E (Individual II:1) were
both identified to have novel hemizygous nonsense mutations in
CHRDL1; c.100G.T, p.(Glu34*) and c.297C.A, p.(Cys99*),
respectively (Figure 1A). Individual II:1 in Family F was found to
have a unique missense mutation in CHRDL1, c.865T.C,
p.(Cys289Arg) (Figure 1A). Similar to other missense mutations
(Family A and [3]), the affected residue is positioned within a
highly conserved cysteine-rich VWFC (Figure 2 and S2 in File S1).
A novel nonsense mutation in CHRDL1, c.229C.T, p.(Arg77*)
was identified in Individual II:2 in Family G. The proband’s
maternal uncle was reported to be affected with megalocornea,
however, no DNA was available for testing.
The proband in Family H (Individual II:1) was initially
identified as harbouring a deletion of CHRDL1 exon 5 by PCR.
In order to confirm the deletion and define the deletion
breakpoints, a fragment of DNA spanning intron 4 to intron 5
was amplified and sequenced, revealing a 9,033 bp deletion and
8 bp insertion; g.109964279_109973310delinsTTATGCTA. The
deletion encompassed exon 5, and partial sequence from intron 4
and intron 5, and is predicted to result in a frameshift and the
introduction of premature termination codon, p.(Glu101Glyfs*42)
(Figure 1B). Segregation analysis of the deletion confirmed that the
proband’s mother is a carrier and the father is wild-type.
Larger deletions encompassing the entire CHRDL1 gene (12
exons) were identified in the affected males in Families I and J, by
PCR. Successful amplification of the closest exons of neighbouring
Phenotypes Associated with CHRDL1
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e104163
Figure 1. X-linked Megalocornea Families A–J. (A) Pedigree of Families A–G. Black shaded squares denote clinically and genetically confirmed
affected males; grey shaded squares denote clinically diagnosed affected males but DNA samples were not available for testing; dotted circles denote
genetically confirmed carrier females; ? = presumed carrier females but DNA samples were not available for testing; clear squares and circles denote
unaffected individuals. Arrowhead indicates proband in each family. Control sequence electropherogram is shown above patient sequence. (B)
Pedigree of Family H and sequence electropherogram showing a 9,033 bp deletion encompassing CHRDL1 exon 5 and 8 bp insertion. (C) Pedigree of
Families I and J. Deletion of the entire CHRDL1 gene (exon 1 to exon 12) in the proband is shown in agarose gel images. The flanking genes, RGAG1
and PAK3 are present. NTC, non-template control (D) Schematic representation of presence or absence of the CHRDL1 gene and flanking genes
RGAG1 and PAK3 (Ensembl nomenclature hg19 genome build) in Families I and J.
doi:10.1371/journal.pone.0104163.g001
Phenotypes Associated with CHRDL1
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genes, RGAG1 and PAK3, demonstrated in both instances that
the deletions identified do not encompass any additional currently
annotated genes (Figure 1C and D).
Ultrasonography as a diagnostic tool for MGC1
Our molecular diagnosis of MGC1 patients, here and previously
[3], has allowed us to define the key phenotypic characteristics of
MGC1 (Table 1) and to differentiate them from PCG (Figure 3).
Patients with MGC1 have a large corneal diameter and thin
cornea, but without corneal oedema or evidence of breaks in
Descemet’s layer. The depth of the anterior chamber in MGC1 is
also typically significantly greater than in patients with PCG.
Ultrasonography is a reliable clinical diagnostic tool to distinguish
the two conditions and, if on ultrasonography, the ratio of the
anterior chamber depth to the total axial length is $0.19 then a
diagnosis of MGC1 is extremely likely, unless there is gross
coexisting axial myopia (.36 mm) (Figure 3; Table 1).
MMR syndrome
The male proband in Family K is the only child of his parents,
who are unrelated. Pregnancy was complicated by 7 days of
vaginal bleeding at 8 weeks gestation, and persistent abdominal
pain from 17 weeks of pregnancy. Due to the abdominal pain,
labour was induced at 39 weeks gestation. Delivery was normal
and he weighed 3.917 kg (91st centile). In the first week of life, he
had some choking episodes, which were thought to be due to
gastro-oesophageal reflux. Thereafter, feeding and weight gain
were satisfactory. He had an apnoeic attack at the age of 7 weeks.
At the age of 3 months, he developed epilepsy and was started on
Sodium Valproate. By 6 months of age, there were concerns about
his psychomotor development. He was found to have global
developmental delay; he only walked at the age of 20 months and
he required speech therapy. Bilateral megalocorneae were
diagnosed in infancy. Physical features at the age of 3 years
included a broad forehead, bilateral megalocorneae, bilateral
epicanthic folds, a tented upper lip and downturned corners of the
mouth (Figure 4B). His occipital frontal circumference (OFC) was
on the 25th centile. Magnetic resonance imaging (MRI) of his
brain and karyotying were reported as normal. He was also very
hypotonic initially, but this has improved. On the basis of his
medical history and physical features, a diagnosis of MMR
syndrome was made. At the age of 10 years, he has moderate
intellectual disability (ID) and a diagnosis of autistic spectrum
disorder. His antiepileptic medication had been discontinued at
the age of 9 years, and he has had no further seizures. He has
episodes of challenging behaviour. Growth parameters were 25th–
50th centile for height, 91st–98th centile for weight, and his OFC
was between the 9th and 25th centile.
Neither of the proband’s parents have a history of megalocor-
nea, ID or epilepsy. There is no paternal contact. His mother had
laser iridotomies at the age of 47 years for bilateral, narrow
anterior chamber drainage angles. He has 2 maternal half-sisters
and a maternal half-brother, who are healthy. His maternal
grandparents are both deceased; his maternal grandfather is
reported to have had ‘‘large eyes’’, cataracts and glaucoma. He
also has 3 paternal half-siblings. Two of them are said to have
epilepsy and ID, although this may be due to infantile meningitis
in one of the children.
Figure 2. Summary of CHRDL1 mutations. (A) Schematic of CHRDL1 protein domains. The following abbreviations are used: SP, signal peptide;
VWFC, von Willebrand factor, type C domain. (B) Schematic of the CHRDL1 gene. (C) CHRDL1 mutations previously reported in X-linked megalocornea
families [3,6]. Frameshift, splicing, nonsense, missense, and whole gene deletion mutations were identified. (D) Novel CHRDL1 mutations identified in
MGC1 families in this study (Families A–J). The dagger ({) indicates Family K with MMR syndrome.
doi:10.1371/journal.pone.0104163.g002
Phenotypes Associated with CHRDL1
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e104163
Identification of a CHRDL1 missense mutation in a male
patient diagnosed with MMR syndrome
Given the rarity of MMR syndrome and the phenotypic
variability reported in the literature [19], we hypothesised that the
condition may not be genetically homogeneous. Since megalocor-
nea is a primary feature of MMR syndrome, we considered that in
this affected male (Individual III:4 Family K, Figure 4), the
megalocornea phenotype may be due to a mutation in CHRDL1.
Sanger sequencing of CHRDL1 revealed a unique hemizygous
missense mutation, c.464G.A, p.(Cys155Tyr) (Table 2) in the
proband within a conserved cysteine-rich VWFC domain. His
unaffected mother was identified to be a heterozygous carrier
(Figure 4A). Despite mutations in CHRDL1 being previously
associated with abnormal brain morphology [3], it was unlikely
that his extraocular features were caused by the CHRDL1
mutation because no other patients with a mutation in CHRDL1
present with developmental delay or any other of the extraocular
phenotypes associated with MMR syndrome [3].
WES analysis of genes previously associated with ID,
epilepsy, seizures and hypotonia
Next, we considered the possibility that the extraocular
phenotypes may be due to a mutation in an X-linked intellectual
disability (XLID) gene in linkage disequilibrium (LD) with the
CHRDL1 mutation, or an autosomal ID gene. We therefore
performed WES with the aim of determining if any additional
genetic variants could be contributing to his extraocular features.
Overall 21,210 exonic and 61,579 total genomic sequence
alterations were identified by WES, with respect to the reference
sequence. As causal variants are hypothesised to be rare, we
filtered the dataset for rare variants with a MAF#0.01 in 1000
Genomes Project, 6500 NHLBI Exome Sequencing Project, and
our internal control data set consisting of 304 exomes. WES
further confirmed the CHRDL1 mutation. We created a database
of genes that have been associated with ID and/or hypotonia and/
or seizures and/or epilepsy, and cross-referenced the filtered rare
variants dataset against this database. Using this approach, we
identified ten rare variants of unknown significance in genes
associated with these neurological phenotypes including four
Figure 3. Comparison between biometry of X-linked megalocornea and congenital glaucoma. (A) AC, anterior chamber depth (back of
cornea to front of lens); AL, axial length (anterior corneal surface to vitreo-retinal interface at the back of the macular). Transverse B-Mode ultrasound
scans demonstrate higher ratio of the AC to AL in megalocornea, 0.204 (left) than congenital glaucoma, 0.135 (right). (B) Ocular coherence
tomography (OCT) images comparing megalocornea (left) and arrested congenital glaucoma (right). Although there is enlargement of the anterior
segment in both conditions, patients with megalocornea tend to have a greater anterior chamber (AC) depth, lower central corneal thickness (CCT),
and deeper anterior chamber angles (ACA) than congenital glaucoma patients.
doi:10.1371/journal.pone.0104163.g003
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heterozygous missense variants, two heterozygous synonymous
variants and four variants present within non-protein coding
regions (59 and 39 UTR regions) (Table S1 in File S1). Each of the
ten variants was validated by direct Sanger sequencing in the
proband and his unaffected mother; paternal DNA was not
available for testing. Two rare autosomal variants in SEMA3E
(MIM 608166) and DDB1 (MIM 600045) were identified in the
proband and his unaffected mother in the heterozygous state,
suggesting that they are unlikely to be causative of the extraocular
phenotypes observed (Table S1 in File S1). Five of the remaining
eight heterozygous variants were identified in genes associated
with autosomal recessive forms of disease (ERCC8, UROC1,
ADCK3, ERCC6, and ERCC3) suggesting that, in isolation, each
of these rare variants would also be unlikely to be causative.
A unique heterozygous variant (g.161326951 A.C) was
identified in the 39UTR of GABRA1 (MIM 137160, Table S1
in File S1). Non-synonymous heterozygous variants in GABRA1
have been associated with juvenile myoclonic epilepsy [33].
However, considering the rarity of critical regulatory elements in
39UTRs, a mutation in this region is usually tolerated. It is
therefore unlikely that this variant would be causative. The
proband’s mother (Individual II:2) was wild-type for this variant,
so either the proband inherited the variant from his father
(Individual II:3), or it is a de novo change. The proband’s father
has no reported history of epilepsy.
A rare heterozygous missense variant, p.(Thr1016Asn), absent
in the proband’s mother, was identified in DIP2B (MIM 611379,
Table S1 in File S1). An expansion of a CGG repeat in the 59UTR
of DIP2B has been reported in two patients with ID (FRA12A)
[34], however no missense variants have been associated with
disease.
A unique hemizygous 1 bp deletion in the 59UTR region of
CUL4B (MIM 300304) was identified in the proband (Table S1 in
File S1). Interestingly, a 2 Kb non-coding deletion that disrupts
the 59UTR of CUL4B has previously been identified to co-
segregate with ID in a single family, resulting in loss of CUL4B
expression, suggestive of a pathogenic effect [35]. Mutations in this
gene in several families with XLID were initially reported in 2007
[36,37]. Interfamilial and intrafamilial phenotypic variability was
noted with regard to several features, including the degree of ID
and the growth parameters (height and OFC). Additional
publications further confirmed the association with moderate to
severe ID and marked speech delay in all patients. Challenging
behaviour, seizures, and a prominent lower lip were also common,
as seen in our patient [38,39].
Notably, CUL4B is situated approximately 900 Kb downstream
of CHRDL1. Since the proband’s mother is also a carrier of this
variant, it is likely that the rare variants identified in CUL4B and
CHRDL1 are in LD. This suggests that MMR in this patient may
be a digenic X-linked trait. However, the proband’s deceased
Figure 4. Novel CHRDL1 missense mutation in a patient diagnosed with MMR. (A) Pedigree of Family K with megalocornea-mental
retardation (MMR) syndrome. Squares, males; circles, females; diamonds, unknown gender; shaded, affected; dotted, carrier; clear, unaffected.
Arrowhead indicates proband. Sequence electropherograms show the CHRDL1 missense mutation c.464G.A; p.(Cys155Tyr), which segregates in
Family K. (B–C) The proband at ages 3, and 6 years, respectively, presented with bilateral megalocorneae, broad forehead, bilateral epicanthic folds, a
tented upper lip, and downturned corners of the mouth. (D–E) Frontal and sides of the proband at age of 10 years.
doi:10.1371/journal.pone.0104163.g004
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maternal grandfather reportedly had ‘large eyes’ in the absence of
extraocular features. This implies that he may have had MGC1
and the CUL4B variant could have occurred as a de novo event in
the proband’s mother. However, the extended family pedigree
indicates a possible paternal transmission of ID and epilepsy in the
proband and his affected half-siblings, which would exclude an X-
linked gene.
Unfortunately, we were not able to test these hypotheses due to
lack of familial DNA samples, so the potential pathogenicity of the
CUL4B and other variants identified, and therefore the genetic
cause of extraocular phenotypes in the proband, remains
unresolved.
Association study
CCT is a normally distributed (Figure S3 in File S1), highly
heritable quantitative trait in the human population [40]. Despite
many GWAS investigating CCT-associated loci, the X-chromo-
some has been largely ignored. We therefore wanted to determine
whether common variants on the X-chromosome in the general
population are associated with CCT. To test this hypothesis we
examined SNP array genotyping data for 1,957 female partici-
pants of British descent from the TwinsUK cohort. Their mean
CCT was 545.24 mm (640.03 mm). The most significant CCT-
associated SNP on the entire X-chromosome was rs149956316
(p = 6.8161026) (Figure S4 in File S1). This SNP is located within
intron 6 of CHRDL1, and the positive effect allele (A) has an MAF
of 0.017 in the TwinsUK dataset (0.008 in the 1000 Genomes
dataset). To assess potential functionality of the rs149956316
variant, we compared the effect of the reference and variant allele
using pre-mRNA splicing prediction programs including Human
Splicing Finder (HSF) [41], NNSPLICE [42], NetGene2 [43] and
SpliceAid [44], but there were no predicted motif alterations or
alternative splicing activity.
Given the known limitations of genomic imputation for variants
with low MAF, we attempted a replication of these results in a
smaller subset of 760 individuals from the TwinsUK cohort, for
which both CCT and genome sequence data were available. We
did not observe a significant effect in this smaller sample and were
unable to replicate the results from the imputation. The current
conflicting data makes it impossible to determine if this non-
validation is the result of insufficient power from the limited
number of samples available, accumulation of potentially influen-
tial imputation mistakes, or if the initial imputed observation was
purely a type one error.
This data initially suggested that the CHRDL1 locus may be a
quantitative trait locus for CCT, however, given the uncertainties
during the replication in directly acquired genotypes (as opposed
to imputed ones), further validation is warranted before the
CHRDL1 locus can be substantiated as influencing CCT in the
general population.
Discussion
All MGC1 families ascertained in this study were found to have
unique CHRDL1 mutations including nonsense mutations
p.(Glu34*), p.(Arg77*), p.(Cys80*) and p.(Cys99*), missense
mutations p.(Cys289Arg) and p.(Cys291Tyr), a frameshift muta-
tion p.(Glu101Glyfs*42), a splice site mutation (c.1247-1_1247del)
and deletions encompassing the entire CHRDL1 transcript. To
date, all patients recruited to our study with a diagnosis of MGC1
were found to have a mutation in CHRDL1 [3].
Members of the transforming growth factor beta (TGF-b)
superfamily, including BMPs, are known to play important roles in
ocular development [45,46]. The concentration of active BMP
ligands is tightly regulated by a collection of secreted proteins,
including the chordin family, which act as BMP antagonists. The
chordin proteins interact with BMPs via the conserved cysteine-
rich VWFC domains [47]. CHRDL1 encodes ventroptin, which
contains three VWFC domains. Consistent with our previous
findings [3], all missense mutations identified to date are located at
highly conserved cysteine residues within these domains, which are
predicted to abrogate interaction with BMPs.
There is an important clinical need to differentially diagnose
MGC1 from PCG. In our molecularly diagnosed cohort of MGC1
patients, we have been able to use ocular imaging define the key
clinical characteristics that assist in differentiating MGC1 from
PCG (Figure 3). Since we have shown that CHRDL1 mutations
do not lead to increased IOP or glaucoma (Table 1) [3], the
repeated examinations that are required to monitor IOP (under
anaesthesia) for PCG patients are not required for MGC1 patients.
A molecular genetic test for CHRDL1 can confirm a diagnosis of
MGC1 and has important implications for clinical care.
As described, megalocornea is also a key pathognomonic feature
of MMR syndrome. Intriguingly, we identified another novel
missense mutation in CHRDL1, c.464G.A; p.(Cys155Tyr) in a
male patient with a diagnosis consistent with MMR syndrome.
This CHRDL1 mutation accounts for the ocular phenotype, and
although the genetic cause of the extraocular phenotypes in this
individual currently remains unexplained, this is the first report
revealing a causative mutation in an MMR case. Recruitment of
more MMR patients and a more comprehensive delineation of
MMR syndrome are essential in order to investigate the
underlying genetic cause(s) of this poorly defined syndrome. Our
findings demonstrate that CHRDL1 should be considered and
screened in males diagnosed with MMR syndrome. Further WES
and copy number variant analysis of male and female subjects will
help to define the contribution of X-linked and autosomal genes to
this syndrome.
We observe that an X-linked locus may be associated with
CCT. In addition to MGC1, corneal thinning is associated with
rare connective tissue disorders such as Brittle cornea syndrome
(BCS; MIM 229200) [48] and Ehlers-Danlos syndrome (EDS;
MIM 130000) [49]. Notably, common variants in genes associated
with certain forms of these rare conditions, ZNF469 (BCS; MIM
612078) and COL5A1 (EDS; MIM 120215), have been shown by
numerous GWAS to be associated with CCT in the general
population [20–25]. The potential association of a CHRDL1 SNP
(rs149956316) with CCT mirrors these findings, and may have not
been detected previously because non-autosomal data have largely
been excluded from the majority of CCT GWAS studies [26].
Currently, the majority of GWAS focus upon analysis of
autosomal variants only, as analysis of sex chromosomes for
GWAS remains technically challenging [26,50]. However, given
the lack of replication in this study, it will be important to test for
association of X-linked loci, and the CHRDL1 locus, with CCT in
male cohorts, because it is possible that phenotypic effects of X-
linked loci (including the CHRDL1 locus) may be masked in
females, who have two copies of the X-chromosome. In males, in
the hemizygous state, we hypothesise that a greater effect on
corneal phenotypes may be observed. Our study highlights the
potential importance of analysing X-chromosome SNP data in
GWAS to identify loci associated with quantitative traits or disease
risk.
Supporting Information
File S1 File includes Figures S1–S4 and Table S1.
(DOC)
Phenotypes Associated with CHRDL1
PLOS ONE | www.plosone.org 10 August 2014 | Volume 9 | Issue 8 | e104163
Acknowledgments
We thank all the families for participating in this research. We also thank
Beverly Scott and Naushin Waseem for DNA extraction and maintaining
the ABI sequencer.
Author Contributions
Conceived and designed the experiments: CJH SJT AJH AED S-SC PGH.
Performed the experiments: AED S-SC HA PGH CV VP. Analyzed the
data: AED S-SC HA PGH CV VP JBR HH EG LK AMJ MR DL MC
JMH IR-E DTP SJT AJH. Contributed reagents/materials/analysis tools:
JCG TRW JBR NC HH EG LK AMJ MR DL MC JMH IR-E DTP SJT.
Contributed to the writing of the manuscript: AED S-SC PGH CV JBR
DTP SJT AJH.
References
1. Meire FM (1994) Megalocornea. Clinical and genetic aspects. Documenta
ophthalmologica Advances in ophthalmology 87: 1–121.
2. Meire FM, Bleeker-Wagemakers EM, Oehler M, Gal A, Delleman JW (1991) X-
linked megalocornea. Ocular findings and linkage analysis. Ophthalmic
paediatrics and genetics 12: 153–7.
3. Webb TR, Matarin M, Gardner JC, Kelberman D, Hassan H, et al. (2012) X-
linked megalocornea caused by mutations in CHRDL1 identifies an essential
role for ventroptin in anterior segment development. American journal of
human genetics 90: 247–59.
4. Chen JD, Mackey D, Fuller H, Serravalle S, Olsson J, et al. (1989) X-linked
megalocornea: close linkage to DXS87 and DXS94. Human genetics 83: 292–4.
5. Gao WL, Zhang SQ, Zhang H, Wan B, Yin ZS (2013) Chordin-like protein 1
promotes neuronal differentiation by inhibiting bone morphogenetic protein-4 in
neural stem cells. Molecular medicine reports 7: 1143–8.
6. Han J, Young JW, Frausto RF, Isenberg SJ, Aldave AJ (2013) X-linked
Megalocornea Associated with the Novel CHRDL1 Gene Mutation p.(Pro56-
Leu*8). Ophthalmic genetics.
7. Sharafieh R, Child AH, Khaw PT, Fleck B, Sarfarazi M (2013) LTBP2 gene
analysis in the GLC3C-linked family and 94 CYP1B1-negative cases with
primary congenital glaucoma. Ophthalmic genetics 34: 14–20.
8. Kupfer C, Kaiser-Kupfer MI (1979) Observations on the development of the
anterior chamber angle with reference to the pathogenesis of congenital
glaucomas. American journal of ophthalmology 88: 424–6.
9. Sarfarazi M, Akarsu AN, Hossain A, Turacli ME, Aktan SG, et al. (1995)
Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos)
to 2p21 and evidence for genetic heterogeneity. Genomics 30: 171–7.
10. Akarsu AN, Turacli ME, Aktan SG, Barsoum-Homsy M, Chevrette L, et al.
(1996) A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos)
maps to the 1p36 region. Human molecular genetics 5: 1199–203.
11. Stoilov IR, Sarfarazi M (2002) The Third Genetic Locus (GLC3C) for Primary
Congenital Glaucoma (PCG) Maps to Chromosome 14q24.3. Invest Ophthal-
mol Vis Sci 2002.
12. Abu-Amero KK, Osman EA, Mousa A, Wheeler J, Whigham B, et al. (2011)
Screening of CYP1B1 and LTBP2 genes in Saudi families with primary
congenital glaucoma: genotype-phenotype correlation. Molecular vision 17:
2911–9.
13. Kaur K, Reddy AB, Mukhopadhyay A, Mandal AK, Hasnain SE, et al. (2005)
Myocilin gene implicated in primary congenital glaucoma. Clinical genetics 67:
335–40.
14. Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, et al. (1999)
Analysis of myocilin mutations in 1703 glaucoma patients from five different
populations. Human molecular genetics 8: 899–905.
15. Ali M, McKibbin M, Booth A, Parry DA, Jain P, et al. (2009) Null mutations in
LTBP2 cause primary congenital glaucoma. American journal of human
genetics 84: 664–71.
16. Desir J, Sznajer Y, Depasse F, Roulez F, Schrooyen M, et al. (2010) LTBP2 null
mutations in an autosomal recessive ocular syndrome with megalocornea,
spherophakia, and secondary glaucoma. European journal of human genetics:
EJHG 18: 761–7.
17. Narooie-Nejad M, Paylakhi SH, Shojaee S, Fazlali Z, Rezaei Kanavi M, et al.
(2009) Loss of function mutations in the gene encoding latent transforming
growth factor beta binding protein 2, LTBP2, cause primary congenital
glaucoma. Human molecular genetics 18: 3969–77.
18. Neuhauser G, Kaveggia EG, France TD, Opitz JM (1975) Syndrome of mental
retardation, seizures, hypotonic cerebral palsy and megalocorneae, recessively
inherited. Zeitschrift fur Kinderheilkunde 120: 1–18.
19. Gutierrez-Amavizca BE, Juarez-Vazquez CI, Orozco-Castellanos R, Arnaud L,
Macias-Gomez NM, et al. (2013) Neuhauser syndrome: a rare association of
megalocornea and mental retardation. Review of the literature and further
phenotype delineation. Genet Couns 24: 185–91.
20. Gao X, Gauderman WJ, Liu Y, Marjoram P, Torres M, et al. (2013) A genome-
wide association study of central corneal thickness in Latinos. Investigative
ophthalmology & visual science 54: 2435–43.
21. Hoehn R, Zeller T, Verhoeven VJ, Grus F, Adler M, et al. (2012) Population-
based meta-analysis in Caucasians confirms association with COL5A1 and
ZNF469 but not COL8A2 with central corneal thickness. Human genetics 131:
1783–93.
22. Lu Y, Dimasi DP, Hysi PG, Hewitt AW, Burdon KP, et al. (2010) Common
genetic variants near the Brittle Cornea Syndrome locus ZNF469 influence the
blinding disease risk factor central corneal thickness. PLoS genetics 6: e1000947.
23. Lu Y, Vitart V, Burdon KP, Khor CC, Bykhovskaya Y, et al. (2013) Genome-
wide association analyses identify multiple loci associated with central corneal
thickness and keratoconus. Nature genetics 45: 155–63.
24. Vitart V, Bencic G, Hayward C, Skunca Herman J, Huffman J, et al. (2010)
New loci associated with central cornea thickness include COL5A1, AKAP13
and AVGR8. Human molecular genetics 19: 4304–11.
25. Vithana EN, Aung T, Khor CC, Cornes BK, Tay WT, et al. (2011) Collagen-
related genes influence the glaucoma risk factor, central corneal thickness.
Human molecular genetics 20: 649–58.
26. Wise AL, Gyi L, Manolio TA (2013) eXclusion: toward integrating the X
chromosome in genome-wide association analyses. American journal of human
genetics 92: 643–7.
27. Piton A, Redin C, Mandel JL (2013) XLID-Causing Mutations and Associated
Genes Challenged in Light of Data From Large-Scale Human Exome
Sequencing. American journal of human genetics.
28. Moayyeri A, Hammond CJ, Hart DJ, Spector TD (2013) The UK Adult Twin
Registry (TwinsUK Resource). Twin research and human genetics: the official
journal of the International Society for Twin Studies 16: 144–9.
29. Doughty MJ, Zaman ML (2000) Human corneal thickness and its impact on
intraocular pressure measures: a review and meta-analysis approach. Survey of
ophthalmology 44: 367–408.
30. Ojaimi E, Rose KA, Morgan IG, Smith W, Martin FJ, et al. (2005) Distribution
of ocular biometric parameters and refraction in a population-based study of
Australian children. Investigative ophthalmology & visual science 46: 2748–54.
31. Lee KE, Klein BE, Klein R, Quandt Z, Wong TY (2009) Association of age,
stature, and education with ocular dimensions in an older white population.
Archives of ophthalmology 127: 88–93.
32. Rud E (1960) Megalocornea in a Danish gipsy family. Acta ophthalmologica 38:
606–17.
33. Cossette P, Liu L, Brisebois K, Dong H, Lortie A, et al. (2002) Mutation of
GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy.
Nature genetics 31: 184–9.
34. Winnepenninckx B, Debacker K, Ramsay J, Smeets D, Smits A, et al. (2007)
CGG-repeat expansion in the DIP2B gene is associated with the fragile site
FRA12A on chromosome 12q13.1. American journal of human genetics 80:
221–31.
35. Whibley AC, Plagnol V, Tarpey PS, Abidi F, Fullston T, et al. (2010) Fine-scale
survey of X chromosome copy number variants and indels underlying
intellectual disability. American journal of human genetics 87: 173–88.
36. Tarpey PS, Raymond FL, O’Meara S, Edkins S, Teague J, et al. (2007)
Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-
linked mental retardation syndrome associated with aggressive outbursts,
seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and
tremor. American journal of human genetics 80: 345–52.
37. Zou Y, Liu Q, Chen B, Zhang X, Guo C, et al. (2007) Mutation in CUL4B,
which encodes a member of cullin-RING ubiquitin ligase complex, causes X-
linked mental retardation. American journal of human genetics 80: 561–6.
38. Badura-Stronka M, Jamsheer A, Materna-Kiryluk A, Sowinska A, Kiryluk K, et
al. (2010) A novel nonsense mutation in CUL4B gene in three brothers with X-
linked mental retardation syndrome. Clinical genetics 77: 141–4.
39. Isidor B, Pichon O, Baron S, David A, Le Caignec C (2010) Deletion of the
CUL4B gene in a boy with mental retardation, minor facial anomalies, short
stature, hypogonadism, and ataxia. American journal of medical genetics Part A
152A: 175–80.
40. Dimasi DP, Burdon KP, Craig JE (2010) The genetics of central corneal
thickness. The British journal of ophthalmology 94: 971–6.
41. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, et al.
(2009) Human Splicing Finder: an online bioinformatics tool to predict splicing
signals. Nucleic acids research 37: e67.
42. Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site
detection in Genie. Journal of computational biology: a journal of computa-
tional molecular cell biology 4: 311–23.
43. Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, et al. (1996)
Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and
global sequence information. Nucleic acids research 24: 3439–52.
44. Piva F, Giulietti M, Nocchi L, Principato G (2009) SpliceAid: a database of
experimental RNA target motifs bound by splicing proteins in humans.
Bioinformatics 25: 1211–3.
45. Wordinger RJ, Clark AF (2007) Bone morphogenetic proteins and their
receptors in the eye. Exp Biol Med (Maywood) 232: 979–92.
Phenotypes Associated with CHRDL1
PLOS ONE | www.plosone.org 11 August 2014 | Volume 9 | Issue 8 | e104163
46. Bakrania P, Efthymiou M, Klein JC, Salt A, Bunyan DJ, et al. (2008) Mutations
in BMP4 cause eye, brain, and digit developmental anomalies: overlap between
the BMP4 and hedgehog signaling pathways. American journal of human
genetics 82: 304–19.
47. Rider CC, Mulloy B (2010) Bone morphogenetic protein and growth
differentiation factor cytokine families and their protein antagonists. The
Biochemical journal 429: 1–12.
48. Abu A, Frydman M, Marek D, Pras E, Nir U, et al. (2008) Deleterious mutations
in the Zinc-Finger 469 gene cause brittle cornea syndrome. American journal of
human genetics 82: 1217–22.
49. Cameron JA (1993) Corneal abnormalities in Ehlers-Danlos syndrome type VI.
Cornea 12: 54–9.
50. Konig IR, Loley C, Erdmann J, Ziegler A (2014) How to include chromosome x
in your genome-wide association study. Genetic epidemiology 38: 97–103.
Phenotypes Associated with CHRDL1
PLOS ONE | www.plosone.org 12 August 2014 | Volume 9 | Issue 8 | e104163
